Privacy and Data Security Update for 2023 (FTC); Managing Artificial Intelligence-Specific Cybersecurity Risks in the Financial Services Sector (U.S. Department of the Treasury); Advancing Governance, Innovation, and Risk Management for Agency Use of Artificial Intelligence (OMB, The White House); Cybersecurity Resources for High-Risk Communities (CISA); Senate Select Intelligence Committee (videos/transcripts); FACT SHEET: Biden-Harris Administration Announces New Actions to Protect U.S. Steel and Shipbuilding Industry from China’s Unfair Practices (The White House); Forget About Chips—China Is Coming for Ships (Foreign Policy); and Foreign Relations of the United States, 1977–1980, Volume IV, National Security Policy (US Department of State).
Critical Mineral Resources: The U.S. Geological Survey (USGS) Role in Research and Analysis; Critical Mineral Resources: National Policy and Critical Minerals List; TikTok and China’s Digital Platforms: Issues for Congress; Defense Primer: National and Defense Intelligence; FISA Section 702 Sunset, Authorization, and Potential Extension; and Community Oriented Policing Services (COPS) Program (all CRS).
Drug Shortage and National Security
Drug Shortage Statistics (American Society of Health-System Pharmacists, ongoing); Building Resilience Into US Prescription Drug Supply Chains (Health Affairs, 2023); Regulating Medicines in a Globalized World: The Need for Increased Reliance Among Regulators and Building Resilience into the Nation’s Medical Product Supply Chains and The Security of America’s Medical Product Supply Chain: Considerations for Critical Drugs and Devices: Proceedings of a Workshop—in Brief (NAPress, 2020, 2021,2022); The Health and National Security Risks of Drug Shortages and Short Supply: The Health and National Security Risks of Drug Shortages (both Senate Committee on Homeland Security, 2023); Federal policies to address persistent generic drug shortages (Brookings, 2023); The National Security Rationale for Stockpiling Key Pharmaceutical Ingredients (Council on Strategic Risks, 2024); Drug Shortages Prior to and During the COVID-19 Pandemic (JAMA, 2024. heavily referenced); FDA Drug Shortages (ongoing); and A Proven Model to Combat U.S. Drug Shortages (Harvard Business Review, 2024).